NCT03663712View on ClinicalTrials.gov

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions
Peritoneal Surface Malignancy
Interventions
BIOLOGICAL

Talimogene Laherparepvec

TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells

Trial Locations (3)

27013

Wake Forest University School of Medicine, Winston-Salem

27710

Duke University Medical Center, Durham

60612

University of Illinois College of Medicine at Chicago, Chicago

All Listed Sponsors
lead

Dan Blazer III, M.D.

OTHER

NCT03663712 - Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies | Biotech Hunter | Biotech Hunter